Literature DB >> 30333228

c-Jun N-terminal kinase (JNK)-mediated phosphorylation of SARM1 regulates NAD+ cleavage activity to inhibit mitochondrial respiration.

Hitoshi Murata1, Cho Cho Khine1, Akane Nishikawa1, Ken-Ichi Yamamoto1, Rie Kinoshita1, Masakiyo Sakaguchi2.   

Abstract

Mitochondrial dysfunction is a key pathological feature of many different types of neurodegenerative disease. Sterile alpha and Toll/interleukin receptor motif-containing protein 1 (SARM1) has been attracting much attention as an important molecule for inducing axonal degeneration and neuronal cell death by causing loss of NAD (NADH). However, it has remained unclear what exactly regulates the SARM1 activity. Here, we report that NAD+ cleavage activity of SARM1 is regulated by its own phosphorylation at serine 548. The phosphorylation of SARM1 was mediated by c-jun N-terminal kinase (JNK) under oxidative stress conditions, resulting in inhibition of mitochondrial respiration concomitant with enhanced activity of NAD+ cleavage. Nonphosphorylatable mutation of Ser-548 or treatment with a JNK inhibitor decreased SARM1 activity. Furthermore, neuronal cells derived from a familial Parkinson's disease (PD) patient showed a congenitally increased level of SARM1 phosphorylation compared with that in neuronal cells from a healthy person and were highly sensitive to oxidative stress. These results indicate that JNK-mediated phosphorylation of SARM1 at Ser-548 is a regulator of SARM1 leading to inhibition of mitochondrial respiration. These findings suggest that an abnormal regulation of SARM1 phosphorylation is involved in the pathogenesis of Parkinson's disease and possibly other neurodegenerative diseases.
© 2018 Murata et al.

Entities:  

Keywords:  ATP; NAD+; SARM1; c-Jun N-terminal kinase (JNK); cell death; mitochondria; nicotinamide adenine dinucleotide (NAD)

Mesh:

Substances:

Year:  2018        PMID: 30333228      PMCID: PMC6295714          DOI: 10.1074/jbc.RA118.004578

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  41 in total

1.  Partial sensitization of human bladder cancer cells to a gene-therapeutic adenovirus carrying REIC/Dkk-3 by downregulation of BRPK/PINK1.

Authors:  Yu Jin; Hitoshi Murata; Masakiyo Sakaguchi; Ken Kataoka; Masami Watanabe; Yasutomo Nasu; Hiromi Kumon; Nam-Ho Huh
Journal:  Oncol Rep       Date:  2011-11-10       Impact factor: 3.906

2.  Attenuated traumatic axonal injury and improved functional outcome after traumatic brain injury in mice lacking Sarm1.

Authors:  Nils Henninger; James Bouley; Elif M Sikoglu; Jiyan An; Constance M Moore; Jean A King; Robert Bowser; Marc R Freeman; Robert H Brown
Journal:  Brain       Date:  2016-02-11       Impact factor: 13.501

3.  The SARM1 Toll/Interleukin-1 Receptor Domain Possesses Intrinsic NAD+ Cleavage Activity that Promotes Pathological Axonal Degeneration.

Authors:  Kow Essuman; Daniel W Summers; Yo Sasaki; Xianrong Mao; Aaron DiAntonio; Jeffrey Milbrandt
Journal:  Neuron       Date:  2017-03-22       Impact factor: 17.173

4.  Ubiquitin is phosphorylated by PINK1 to activate parkin.

Authors:  Fumika Koyano; Kei Okatsu; Hidetaka Kosako; Yasushi Tamura; Etsu Go; Mayumi Kimura; Yoko Kimura; Hikaru Tsuchiya; Hidehito Yoshihara; Takatsugu Hirokawa; Toshiya Endo; Edward A Fon; Jean-François Trempe; Yasushi Saeki; Keiji Tanaka; Noriyuki Matsuda
Journal:  Nature       Date:  2014-06-04       Impact factor: 49.962

5.  Neurodegeneration in C. elegans models of ALS requires TIR-1/Sarm1 immune pathway activation in neurons.

Authors:  Julie Vérièpe; Lucresse Fossouo; J Alex Parker
Journal:  Nat Commun       Date:  2015-06-10       Impact factor: 14.919

6.  Opening of the mitochondrial permeability transition pore causes depletion of mitochondrial and cytosolic NAD+ and is a causative event in the death of myocytes in postischemic reperfusion of the heart.

Authors:  F Di Lisa; R Menabò; M Canton; M Barile; P Bernardi
Journal:  J Biol Chem       Date:  2000-11-09       Impact factor: 5.157

7.  SARM inhibits both TRIF- and MyD88-mediated AP-1 activation.

Authors:  Jun Peng; Quan Yuan; Bin Lin; Porkodi Panneerselvam; Xiaowei Wang; Xiao Lei Luan; Soon Kok Lim; Bernard P Leung; Bow Ho; Jeak Ling Ding
Journal:  Eur J Immunol       Date:  2010-06       Impact factor: 5.532

8.  Bioenergetic analysis of isolated cerebrocortical nerve terminals on a microgram scale: spare respiratory capacity and stochastic mitochondrial failure.

Authors:  Sung W Choi; Akos A Gerencser; David G Nicholls
Journal:  J Neurochem       Date:  2009-03-23       Impact factor: 5.372

9.  SARM1 and TRAF6 bind to and stabilize PINK1 on depolarized mitochondria.

Authors:  Hitoshi Murata; Masakiyo Sakaguchi; Ken Kataoka; Nam-Ho Huh
Journal:  Mol Biol Cell       Date:  2013-07-24       Impact factor: 4.138

10.  MyD88-5 links mitochondria, microtubules, and JNK3 in neurons and regulates neuronal survival.

Authors:  Younghwa Kim; Ping Zhou; Liping Qian; Jen-Zen Chuang; Jessica Lee; Chenjian Li; Costantino Iadecola; Carl Nathan; Aihao Ding
Journal:  J Exp Med       Date:  2007-08-27       Impact factor: 14.307

View more
  24 in total

Review 1.  Emergence of SARM1 as a Potential Therapeutic Target for Wallerian-type Diseases.

Authors:  Heather S Loring; Paul R Thompson
Journal:  Cell Chem Biol       Date:  2019-11-21       Impact factor: 8.116

Review 2.  NAD+ in Brain Aging and Neurodegenerative Disorders.

Authors:  Sofie Lautrup; David A Sinclair; Mark P Mattson; Evandro F Fang
Journal:  Cell Metab       Date:  2019-10-01       Impact factor: 27.287

Review 3.  Wallerian degeneration as a therapeutic target in traumatic brain injury.

Authors:  Vassilis E Koliatsos; Athanasios S Alexandris
Journal:  Curr Opin Neurol       Date:  2019-12       Impact factor: 5.710

Review 4.  Axon injury signaling and compartmentalized injury response in glaucoma.

Authors:  Stephanie B Syc-Mazurek; Richard T Libby
Journal:  Prog Retin Eye Res       Date:  2019-07-10       Impact factor: 21.198

Review 5.  SARM1 can be a potential therapeutic target for spinal cord injury.

Authors:  Qicheng Lu; Benson O A Botchway; Yong Zhang; Tian Jin; Xuehong Liu
Journal:  Cell Mol Life Sci       Date:  2022-02-28       Impact factor: 9.261

6.  Passenger Mutations Confound Phenotypes of SARM1-Deficient Mice.

Authors:  Melissa B Uccellini; Susana V Bardina; Maria Teresa Sánchez-Aparicio; Kris M White; Ying-Ju Hou; Jean K Lim; Adolfo García-Sastre
Journal:  Cell Rep       Date:  2020-04-07       Impact factor: 9.423

7.  Phosphorylation at S548 as a Functional Switch of Sterile Alpha and TIR Motif-Containing 1 in Cerebral Ischemia/Reperfusion Injury in Rats.

Authors:  Tao Xue; Qing Sun; Yijie Zhang; Xin Wu; Haitao Shen; Xiang Li; Jiang Wu; Haiying Li; Zhong Wang; Gang Chen
Journal:  Mol Neurobiol       Date:  2020-09-23       Impact factor: 5.590

Review 8.  NAD+ metabolism: pathophysiologic mechanisms and therapeutic potential.

Authors:  Na Xie; Lu Zhang; Wei Gao; Canhua Huang; Peter Ernst Huber; Xiaobo Zhou; Changlong Li; Guobo Shen; Bingwen Zou
Journal:  Signal Transduct Target Ther       Date:  2020-10-07

Review 9.  Programmed axon degeneration: from mouse to mechanism to medicine.

Authors:  Michael P Coleman; Ahmet Höke
Journal:  Nat Rev Neurosci       Date:  2020-03-09       Impact factor: 34.870

10.  Neuropathy target esterase (NTE/PNPLA6) and organophosphorus compound-induced delayed neurotoxicity (OPIDN).

Authors:  Rudy J Richardson; John K Fink; Paul Glynn; Robert B Hufnagel; Galina F Makhaeva; Sanjeeva J Wijeyesakere
Journal:  Adv Neurotoxicol       Date:  2020-03-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.